In this context, the role of activin type II receptor (ActRII) ligands, including FSTL3, which is an endogenous inhibitor of ActRII ligands that increases with aging and HF severity in humans [59], might be crucial. This evidence concerns the gene ACVR2A and hydrops fetalis.